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S U M M A R Y
According to the World Health Organization (WHO), 10.4 million people died of tuberculosis (TB) in
2015, and the disease is now the number one cause of death from a preventable infectious disease
worldwide. A bold vision is needed from global leaders to end the TB epidemic and plans to this end have
been proposed. However enthusiasm must be matched by tangible and achievable goals based on the
science and available funding. In order to reach the target and goals set by the WHO End TB Strategy, the
challenges for TB eradication need to be addressed. In order to achieve the targets, several areas need to
be bolstered, including the requirement to better identify and treat existing drug-susceptible cases and
diagnose all the drug-resistant forms of the disease. Although treatment is available for most TB patients,
stock-outs and other delays are problematic in some settings, resulting in ongoing transmission,
especially for the drug-resistant forms of the disease. Despite the fact that a majority of multidrug-
resistant cases are linked to treatment, the cure rate is only 50%, which highlights the need for safer,
shorter, and more efﬁcacious drug regimens that are more tolerable to patients. Prospects for a more
efﬁcacious vaccine are limited, with no correlates of protection identiﬁed; thus the availability of a
vaccine by 2025 is highly improbable. Support for instituting infection control methods should be
prioritized to subvert transmission while patients seek treatment and care. Finally, more adequate
ﬁnancial mechanisms should be instituted to reduce patient expenditures and support national TB
programs. Moreover, funding to support basic science, drug development, clinical trials, vaccine
development, diagnostics, and implementation research needs to be secured in order to reduce global TB
incidence in the future.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
On May 19, 2014, the 67th World Health Assembly adopted the
World Health Organization (WHO) Global Strategy and Targets for
Tuberculosis Prevention, Care and Control after 2015.1 The post-
2015 global tuberculosis (TB) plan, known as the End TB Strategy,2
was formed and developed through consultation with a wide range
of stakeholders. The strategy sets ambitious goals for the post-
2015 agenda. A 90% reduction in TB-related mortality, an 80%
decline in TB incidence, and the abolition of catastrophic
expenditures for TB-affected people by 2030 are targeted by this
strategy. Strong government commitment and adequate ﬁnancing
from all countries, together with community engagement and
appropriate investments in research, are necessary in order to
reach these targets.3 The strategy has a vision of making the world* Corresponding author. Tel.: +1 520-547-3449.
E-mail address: mschito@c-path.org (M. Schito).
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1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International S
(http://creativecommons.org/licenses/by/4.0/).free of TB, with zero deaths, disease, and suffering due to the
disease. An admirable strategy but how realistic is it?
Mycobacterium tuberculosis can cause a spectrum of clinical
manifestations, from latent asymptomatic infection and asymp-
tomatic sub-clinical disease to the full spectrum of symptomatic
clinical disease affecting any organ of the body. Thus the true
burden of TB remains difﬁcult to quantify. Although there are
several commercially approved culture and molecular-based
diagnostic tests to identify active TB, the tools used programmati-
cally in high burden countries still rely on the century-old method
of smear microscopy and in-house culture, which is known to miss
many cases due to poor accuracy and the need for specialized
culture facilities.
For latent M. tuberculosis infection (LTBI), the accuracy of these
assays at predicting TB disease during the lifetime of the individual
or identifying previous exposure remains to be seen.4,5 Exposure
would include those who are colonized, as well as those
individuals who have been able to inhibit the establishment of
infection. The diagnosis and treatment of LTBI is a tool for global TBication versus control. Int J Infect Dis (2016), http://dx.doi.org/
ociety for Infectious Diseases. This is an open access article under the CC BY license
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diagnosis and treatment of LTBI under operational ﬁeld conditions
are scarce from high TB burden countries, and the beneﬁts of LTBI
management remain to be determined. Primary healthcare clinics
in Sao Paulo reported high proportions of contacts without
evaluation, incomplete assessments, and incorrect records of
contraindication to LTBI treatment, and a lack of notes regarding
the identiﬁcation and evaluation of contacts.6 This highlights the
need for on the ground improvements in infrastructure and
organization for routine contact investigation. The need is global in
scope and includes improved coordination of TB screening in
Europe as well, in order to implement the goals outlined by the
End TB Strategy.7
In 1998, Dowdle proposed a deﬁnition of ‘control’ as a reduction
in the incidence, prevalence, morbidity, or mortality of an
infectious disease to a locally acceptable level; ‘elimination’ as a
reduction to zero of the incidence of disease or infection in a
deﬁned geographical area; and ‘eradication’ as a permanent
reduction to zero of the worldwide incidence of infection.8
Inherent in these deﬁnitions of control and elimination is the
requirement of continued interventions to prevent the re-
emergence and re-establishment of transmission. It is this need
for continued surveillance and intervention after reaching control
or elimination targets that is essential to sustain disease control.
However, most countries typically cut budgets in response to
declining disease incidence and prevalence rates. Neglect or
complete cessation of intervention activities can lead to the re-
emergence of the disease in vulnerable populations.
2. Eradication
In theory, if adequate funding, appropriate tools, and political
commitment were available, all infectious diseases including TB
would be eradicable. The important indicators of eradicability
include the availability of effective interventions, including
practical, affordable, and implementable diagnostics, prevention
tools, treatment, and adequate funding.8 To date, only smallpox9
and rinderpest10 have been successfully eradicated. Both diseases
had these tools available, coupled with serious political commit-
ment to effectively interrupt transmission and reduce prevalence
to zero. Currently, six ongoing programs are in progress:
poliomyelitis, yaws, dracunculiasis, malaria, hookworm, and
yellow fever. In addition, the International Task Force for Disease
Eradication at the Carter Center has identiﬁed neonatal tetanus,
leprosy, onchocerciasis, trachoma, and lymphatic ﬁlariasis as
additional potential candidates for elimination.
There are three major pre-conditions that make it scientiﬁcally
more feasible to eradicate a disease: (1) epidemiological vulnera-
bility, (2) effective interventions, and (3) feasibility of elimination.
For TB, the disease is not vulnerable to eradication for the following
reasons: it is easily transmitted; transmission occurs throughout
the year and is not linked to a cyclical disease cycle (e.g., like
inﬂuenza); there is no natural immunity to prevent re-infection; it
is not easily diagnosed (current estimates from the WHO suggest
that nearly one third of all TB cases are not detected); disease
relapse is documented in a proportion of patients who complete
treatment; and there is an LTBI reservoir that can re-activate at any
time in an individual’s lifetime. In addition, TB elimination has
never been documented from any country in the world, indicating
that the likelihood of achieving global TB eradication is low.
3. Prevention tools
In regards to effective preventive interventions, a safe and
effective M. tuberculosis vaccine is not available despite intense
research efforts over the past two decades. The current bacillePlease cite this article in press as: Schito M, et al. Tuberculosis erad
10.1016/j.ijid.2016.11.007Calmette–Gue´rin (BCG) vaccine in use today does not prevent
infection but may reduce mortality in young recipients. BCG has
been implemented for nearly a century, and despite its widespread
use, TB continues to be a major global problem. A vaccine to
prevent M. tuberculosis infection or disease remains an important
tool for elimination, but the development of such a vaccine is
considerably hindered by the complex biology of M. tuberculosis
and the lack of basic information on protective immune
responses.11 There is currently no correlate of protection identiﬁed
for a vaccine and no prospects of what protective host responses
the vaccine should mount, or what response magnitudes are
needed. Furthermore, immune responses may need to be elicited at
mucosal surfaces to control or prevent M. tuberculosis infection,
since the site of infection is the lung. Surprisingly little attention
has been given to the understanding of M. tuberculosis mucosal
immune responses in the lung. In the absence of this critical
information there is no easy path forward and thus one cannot
generate a timeline for the development of an effective preventa-
tive TB vaccine. Even if a correlate of protection is identiﬁed and a
promising vaccine construct is identiﬁed, it will take an additional
10 years to complete the required clinical trials. Therefore, as of
2017, it is impossible to expect a vaccine by 2025 (Figure 1).
4. Chemotherapy
A single tool (such as a vaccine) can impact incidence and
prevalence over time but cannot eliminate TB. Disease elimination
will require a well-coordinated and long-term funded effort. Drugs
can help and these represent another tool in the global health
toolkit. Nevertheless, as has been observed over the past half
century since effective TB drugs and treatment regimens have been
available, it requires a massive coordination effort and resources to
scale up and reach a critical level of penetration, with backup for
tackling the development of resistance. A new diagnostic, such as
the GeneXpert MTB/RIF assay is important for early detection and
reducing the duration of infectiousness, but by itself it has not been
shown to affect treatment outcomes.12 The lack of adequate
funding to develop new tools and for scaling up and implementing
the existing tools, coupled with the lack of any prospect of a
preventative vaccine within the next decade, makes it likely that
the End TB Strategy regarding global elimination will not
materialize.
Current standard TB drug therapy can be effective and
affordable, but is not well tolerated, is toxic, and the treatment
duration is too long. Moreover, the issue of drug resistance has
been increasing steadily, requiring longer, more toxic and painful
treatments that are more expensive, steeped in stigma, and require
additional clinical monitoring, and which are not affordable or
available to most multidrug-resistant (MDR) TB patients. Recent
reports of new TB patients with diabetes mellitus at increased risk
of drug-resistant TB disease suggest that new synergies between
infectious and non-infectious diseases may be important to
monitor.13,14
After many years of ﬁnancially constrained research, bedaqui-
line and delamanid were recently approved by stringent regulatory
authorities to treat MDR-TB in 2012 and 2014, respectively. As of
2016, no ofﬁcial drug susceptibility test (DST) method has been
approved to monitor the eventual development of resistance to
these new drugs, despite their availability and use over the past
several years to treat patients at a programmatic level. Bedaquiline
and delamanid may save lives for difﬁcult to treat infections, but it
remains to be determined whether they will have any impact on
the global epidemiology of TB for which shorter and more effective
regimens for both drug-susceptible disease and LTBI are neces-
sary.3 The development of more potent and better-tolerated drug
regimens, optimization of drug exposure for the component drugs,ication versus control. Int J Infect Dis (2016), http://dx.doi.org/
Figure 1. Projected decline in global TB incidence based on the deployment and optimization of new emerging tools and the challenges associated with their successful
introduction. Reproduced and modiﬁed with the permission of the World Health Organization.
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accurate biomarkers of treatment effect, and the assessment of
new strategies for implementing regimens in the ﬁeld remain key
priority areas for research and are being addressed by the Critical
Path to TB Drug Regimens (http://www.cptrinititive.org) along
with stakeholder partners. Nanotechnology drug delivery systems
have considerable potential for the treatment of TB. The novel
properties of nanotechnology enable improvements in the
bioavailability of drugs, can reduce the dosage and frequency of
administration, and may solve the problem of non-adherence to
prescribed therapy, which is a major obstacle to the control of TB.15
5. Diagnostics and drug resistance
Many patients do not have access to laboratory facilities that
can determine TB-DST beyond ﬁrst-line drugs. New diagnostic
tools are particularly needed in order to improve the diagnosis of
disease and latent infection, the rapid detection of drug resistance,
and for use across special (HIV and pediatric) populations. Several
new diagnostic devices or methods have been endorsed by the
WHO since 2007 and many others are under investigation. Despite
the WHO endorsement of diagnostic tools, the reality in the ﬁeld is
that many have not been rolled-out or sufﬁciently scaled-up. As a
result many TB patients are assessed by sputum smear microscopy
and started on treatment empirically. Targeted sequencing is being
optimized directly from sputum (in the absence of culture) to
identify mutations within days,16 and a global data-sharing
platform (https://platform.reseqtb.org) was recently launched to
address the bioinformatics need for predicting drug resistance
using sequencing technologies.17 This approach may be potentially
useful together with routine diagnostic tests in order to quickly
build up individualized therapeutic regimens in severe cases of
MDR-TB and extensively drug-resistant TB (XDR-TB),3 as well as
inform surveillance programs. Although sequencing is not
immediately implementable in all healthcare settings, resources
must be developed to support the bioinformatic sequencing needs
as the technology, cost, turnaround times, and clinical outcomes
improve.Please cite this article in press as: Schito M, et al. Tuberculosis erad
10.1016/j.ijid.2016.11.007The current and future control of MDR-TB relies signiﬁcantly on
the correct and optimal use of new diagnostics and new drugs,
together with the consistent application of the following ﬁve core
interventions at the programmatic level. First is the need to
prevent the development of MDR-TB through high quality
treatment of drug-susceptible TB. However, recent modeling
suggests that the vast majority of MDR-TB is spread through
transmission rather than by programmatic mismanagement,18
highlighting the need to bolster infection control efforts. Second is
the need to expand rapid testing and detection of drug-resistant
TB. This requires signiﬁcant funding, infrastructure, and support.
Third is the need to provide immediate access to effective
treatment and proper care. From the 2015 Global WHO TB report,
a major success is the fact that >90% of MDR-TB patients who are
identiﬁed are linked to care and put on treatment. However, more
work is needed to address the need to have shorter, safer, and more
effective regimens. Fourth is the requirement to prevent transmis-
sion through infection control, which is an ongoing need in most
settings.19–21 Fifth is the need for an increase in political
commitment and ﬁnancing (programmatic and research). Report-
edly in excess of four billion dollars is desperately needed to
address the now number one global infectious disease killer.22
Despite more than 1.8 million people dying of TB in 2015, funding
for TB programs through the US Global Health Program account
totaled US$191 million for 2017, a US$45 million decrease (19%)
below the FY16 level.23
6. Conclusions
Whilst some countries may be able to shift resources to achieve
the goal of control (deﬁned as <10 TB cases per 100 000), many
confounding issues including but not limited to increased
migration, war, refugee crises, poverty, comorbidities, non-
tuberculous mycobacteria, animal TB, and malnutrition, together
with the identiﬁed funding gap, thwart the goal of reducing TB
prevalence. This will become apparent as new disease estimates
using molecular methods begin to trickle in and the size of the
MDR-TB population is better characterized on a global scale,ication versus control. Int J Infect Dis (2016), http://dx.doi.org/
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essential to increase resources to bolster the support to address the
issues that have been neglected. For too long the response of the
Global Fund and other donor agencies for TB investments has been
unbalanced, resulting in TB languishing second rate to HIV and
malaria.
Until many of these scientiﬁc and funding challenges are
addressed, the likelihood of achieving goals beyond controlling TB
is bleak. Even if it was scientiﬁcally feasible to eradicate TB, there
are operational and health systems issues that must be considered,
such as the perceived burden of the disease, expected cost of
eradication, synergy of eradication efforts with other interven-
tions, and the necessity for eradication rather than control.8 In
addition, since the poorest and socially excluded groups carry the
largest burden of disease, it is essential to properly address the
social determinants of health through poverty reduction measures
and to target interventions at high-risk populations,24 including
the millions who are displaced. The spread of MDR-TB requires
special attention and highlights the need to bolster research on
new TB drugs, vaccines, and diagnostics. There is a need to
differentiate the development of new technologies, including the
endorsement, adoption, and scale-up, from the training, imple-
mentation, and health systems challenges on a global scale.
Although signiﬁcant progress has being made in the ﬁght against
TB over the last 25 years, signiﬁcant challenges remain and much
greater political and funder investment is still needed to achieve
global elimination.
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